Eli Lilly has increased its annual sales forecast by $3 billion, attributing the rise to expanded manufacturing capacity for its popular weight-loss drug Zepbound. The company’s shares jumped 13% following the announcement, potentially adding nearly $100 billion to its market value. For the first time, Zepbound’s quarterly sales surpassed $1 billion since its launch in late 2023, helping boost the company’s financial outlook.
Chief Scientific Officer Daniel Skovronsky highlighted that Eli Lilly has committed over $18 billion to new and updated manufacturing facilities in the U.S. and Europe to meet the rising demand for weight-loss treatments. This investment includes a $5.3 billion facility in Indiana for producing tirzepatide, the active ingredient in both Zepbound and Mounjaro. The company’s increased manufacturing capacity has enabled it to fulfill more orders and stock up wholesalers.
The report indicates a growing market for weight-loss drugs, with some analysts projecting it could exceed $150 billion by the early 2030s. Despite high demand, the supply of these drugs has often been tight, but Eli Lilly has managed to increase availability, leading to significant sales growth. CEO David Ricks noted the strong consumer demand for Zepbound, which has maintained stable pricing throughout the quarter.
Eli Lilly’s adjusted profit forecast for 2024 has been raised to $16.10 to $16.60 per share, up from a previous estimate of $13.50 to $14. Additionally, the overall revenue forecast has been increased to $45.4 billion to $46.6 billion. The company plans to launch new single-dose vials of Zepbound in the U.S. soon, further increasing its manufacturing efficiency. Despite the improved supply balance, the company anticipates periodic supply tightness due to ongoing high demand.
